Clinical Trials

Sigilon initiated a Phase 1/2 study in previously treated male patients with severe or moderately severe hemophilia A. The study will evaluate the safety, tolerability, and efficacy of SIG-001 in adult male patients with severe or moderately severe hemophilia A without inhibitors across clinical centers in the United States (US) and the European Union (EU).

To learn more about the study, please visit the study listing on clinicaltrials.gov or on EudraCT.